IN MANY PATIENTS WITH ABDOMINAL OR PELVIC MALIGNANCIES, surgical treatment
|
|
- Rose Washington
- 8 years ago
- Views:
Transcription
1 Sugarbaker, Cancerología 3 (2008): Washington Cancer Institute, Washington, DC, USA Overview of Peritoneal Carcinomatosis Paul H. Sugarbaker 1 Abstract IN MANY PATIENTS WITH ABDOMINAL OR PELVIC MALIGNANCIES, surgical treatment failure is isolated to the resection site or to peritoneal surfaces. Elimination of peritoneal surface spread will probably have an impact on survival. Prior to the use of cytoreductive surgery and hiperthermic intraperitoneal chemotherapy, carcinomatosis was a uniformly fatal condition eventually resulting in intestinal obstruction over the course of months or years. This procedure remains controversial, but in experienced centers the application of this new and more comprehensive cancer management strategy remains broad. Key words: Carcinomatosis, Cytoreductive Surgery, HIPEC Resumen La falla del tratamiento quirúrgico se presenta en el sitio de la resección o en la superficie peritoneal en muchos pacientes con cáncer localizado en el abdomen o en la pelvis. La eliminación de la diseminación peritoneal puede tener un impacto en la super vivencia. Anteriormente al uso de la cirugía citorreductiva y la quimioterapia intraperitoneal hipertérmica, la carcinomatosis peritoneal era una condición uniformemente fatal, que eventualmente desarrollaba obstrucción intestinal en el transcurso de meses o años. Este procedimiento es controversial, pero esta nueva estrategia de manejo oncológico se realiza en activamente en centros con experiencia. Palabras clave: Carcinomatosis, Cirigía Citorreductiva, HIPEC Correspondence: Paul H. Sugarbaker, MD, FACS, FRCS Director, Program in Peritoneal Surface Malignancy, Washington Cancer Institute 106 Irving St., NW, Suite Washington, DC 20010, USA. Phone: Fax: Paul.Sugarbaker@medstar.net 119
2 Overview of Peritoneal Carcinomatosis Introduction Changes in the use of chemotherapy in patients with peritoneal carcinomatosis, peritoneal sarcomatosis, and peritoneal mesothelioma have shown favorable results of treatment. A change in route of drug administration has occurred: Chemotherapy is given intraperitoneally, or by combined intraperitoneal (ip) and intravenous (iv) routes. In this new strategy, iv chemotherapy alone is rarely indicated. Also, a change in timing has occurred: Chemotherapy begins in the operating room and may be continued for the first 5 postoperative days. A change in selection criteria of treatment of cancer has also occurred. The lesion size (LS) of peritoneal implants is of crucial importance. Only patients with small-sized ip tumor nodules with limited distribution within the abdomen and pelvis are likely to show prolonged benefit. In order to achieve maximum benefit meticulous cytoreductive surgery is necessary prior to the ip chemotherapy instillation. Aggressive treatment strategies for large-volume invasive carcinomatosis will not produce long-term benefits and are often the cause of excessive morbidity or mortality. The initiation of treatments for peritoneal surface malignancy (PSM) must occur as early as possible in the natural history of these diseases in order to achieve the greatest benefits. A definitive role for prevention of carcinomatosis for patients at high risk for peritoneal dissemination has been demonstrated. The greatest change that now needs to occur with PSM is a change in oncologists attitudes toward these diseases. They may be cured if treated early with aggressive local-regional treatment strategies. Background Cancers that occur within the abdomen and pelvis will disseminate by three different routes: hematogenous metastases, lymphatic metastases, and through peritoneal spaces to surfaces within the abdomen and pelvis. In a substantial number of patients, surgical treatment failure is isolated to the resection site or to peritoneal surfaces. This leads to a hypothesis that suggests that the elimination of peritoneal surface spread will have an impact on the survival of these cancer patients. There can be no doubt that a leading cause of death and suffering in patients with these malignancies is progression of peritoneal surface disease. Prior to the use of cytoreductive surgery and ip chemotherapy, carcinomatosis was a uniformly fatal condition eventually resulting in intestinal obstruction over the course of months or years. Occasionally, patients with low-grade malignancies, such as pseudomyxoma peritonei, survived for several years, but all endresult reporting have shown fatal outcomes. Peritoneal-Plasma Barrier IP chemotherapy gives high response rates within the abdomen because the peritoneal-plasma barrier provides dose-intensive therapy. (1) Figure 1 shows that large molecular weight substances such as mitomycin C (MMC) are confined to the abdominal cavity for long time periods which means that the exposure of peritoneal surfaces to pharmacologically active molecules can be increased considerably by giving the drugs via the ip route rather than by the iv route. (2) For chemotherapy agents used to treat peritoneal carcinomatosis or peritoneal sarcomatosis, the area under the curve (AUC) ratios of ip to iv exposure are favorable. Table 1 presents the AUC (ip/ iv) for the drugs in routine clinical use in patients with peritoneal seeding. (3-5) In the author s studies, these include 5-fluorouracil (5-FU), MMC, doxorubicin, cisplatin, paclitaxel, and gemcitabine. One should not assume that the ip administration of chemotherapy eliminates their systemic toxicities. Although the drugs sequestered within the peritoneal space, they eventually are cleared into the systemic circulation. For this reason, the safe dose of most drugs instilled into the peritoneal cavity is similar to the iv dose. The exceptions are drugs with hepatic degradation, such as 5-FU and gemcitabine. An increased dose of approximately 120
3 Sugarbaker, Cancerología 3 (2008): Table 1 Area under curve ratios of peritoneal surface exposure to systemic exposure for drugs used to treat intraabdominal cancer. Drug 5-fluorouracil Mitomycin C Doxorubicin Cisplatin Paclitaxel Gemcitabine Molecular Weight µg/ml Time (Hours) µmol/l Peritoneal fluid 50% is possible with 5-FU. The dose for a 5-day course of iv 5-FU is approximately 500 mg/m 2 / day; for ip 5-FU, the dose is 750 mg/m 2 /day. This approximate 50% increase in dose of 5-FU is of benefit in eliminating peritoneal carcinomatosis. Tumor Cell Entrapment AUC Urine Plasma Portal plasma Figure 1 Large molecular weight compounds, when instilled into the peritoneal cavity, are sequestered at the site for long time periods. The physiologic barrier to the release of ip drugs is called the peritoneal plasma barrier. In this experiment, 15 mg MMC was infused into the cavity as rapidly as possible. IP, iv portal venous pressure and urine MMC concentrations were determined by high pressure liquid chromatography assay. The tumor cell entrapment hypothesis explains the rapid progression of PSM in patients who undergo treatment of carcinomatosis using surgery alone. This theory relates the high incidence and rapid progression of peritoneal surface implantation to free ip tumor emboli as a result of serosal penetration by cancer; leakage of malignant cells from transected lymphatics; dissemination of malignant cells directly from the cancer specimen as a result of surgical trauma and backflow of venous blood; fibrin entrapment of intraabdominal tumor emboli on traumatized peritoneal surfaces; and promotion of these entrapped tumor cells through growth factors involved in the wound healing process. This phenomenon may cause a high incidence of surgical treatment failure in patients treated for primary GI cancer. Also, the reimplantation of malignant cells into peritonectomized surfaces in a reoperative setting must be expected. Chemotherapy used in the perioperative period not only directly destroys tumor cells but it also eliminates viable platelets while blood cells and monocytes form the peritoneal cavity which diminishes the promotion of tumor growth associated with the wound healing process. Consequently, the results of ip chemotherapy show a reduction in local cancer recurrence and peritoneal surface recurrence in patients with intraabdominal cancer. Removal of the leukocytes and monocytes also decreases the ability of the abdomen to resist an infectious process; therefore, strict aseptic technique is imperative when administering chemotherapy or when handling tubes and drains. In order to interrupt implantation of tumor cells at the resection site and on other abdominal and pelvic surfaces, the abdominal cavity is flooded with chemotherapy in a large volume of fluid during the operation (HIPEC = heated intraperitoneal chemotherapy) and in he early postoperative period (EPIC = early postoperative intraperitoneal chemotherapy). Most patients with a guarded prognosis may also receive adjuvant ip and systemic chemotherapy. (6) Therefore, the strategy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis involves not only a change in the route (from iv to ip) but also a change in the timing (postoperative to perioperative) of chemotherapy administration. This new approach to surgical treatment of abdominal and pelvic malignancy begins in the operating room after a complete resection of a primary cancer or after the complete cytoreduction of peritoneal carcinomatosis, peritoneal 121
4 Overview of Peritoneal Carcinomatosis sarcomatosis, or peritoneal mesothelioma. The proper placement of tubes and drains and temperature probes is needed prior to initiation of HIPEC. Suture lines or repair of seromuscular tears occurs after the ip chemotherapy is completed. Before abdominal closure, the temperature probes are removed but the tubes and drains are left in place for EPIC. Proper Patient Selection for IP Chemotherapy Perhaps the greatest impediment to lasting benefits from ip chemotherapy should be attributed to improper patient selection. In the past, most ip chemotherapy protocols, from a theoretical perspective, wound not benefit much, if at all. A great number of patients with gross intraabdominal disease were treated. Even with extensive prior cytoreductive surgery, the patient is not likely to have lasting benefit. Rapid recurrence of ip cancer combined with progression of lymph nodal or systemic disease were likely to interfere with any long-term benefits in these patients. Clinical research has shown that patients who benefit will have minimal disease isolated to peritoneal surfaces that have access to chemotherapy so that complete eradication of disease can occur. Partial responses are not of great benefit in PSMs. Complete and durable responses are the reasonable goal. Of course, the extent of disease when the patient starts treatment will have great bearing on the response achieved. Early and asymptomatic patients must be selected for ip chemotherapy protocols. Clinical Assessments of PSM In the past, peritoneal carcinomatosis was considered to be a fatal disease process. The only assessment used was either carcinomatosis present with a presumed fatal outcome or carcinomatosis absent with curative options available. Currently, there are four important clinical assessments of PSM that need to be used to select patients who will benefit from treatment protocols: the invasive character of the malignancy, the preoperative computed tomography (CT) scan of abdomen and pelvis, the Peritoneal Cancer Index (PCI), and the completeness of cytoreduction score (CC). (7-11) Clinical Evidence that Cytoreductive Surgery and IP Chemotherapy Benefits Patients with PSM Treatments for peritoneal carcinomatosis and sarcomatosis have been shown to provide survival with a portion of patients alive a 5 years and considered cured. The strategy for treating these patients has always involved three essential components: first is a complete cytoreduction utilizing peritonectomy procedures with an attempt to removal all visible tumor; assuming that microscopic residual disease will eventuate in recurrence in all these patients, the second essential component is perioperative ip chemotherapy; and, it is becoming increasingly clear that proper patient selection is the third essential component of these treatment strategies. Although no one questions the essential nature of complete cytoreduction and accurate patient selection, many oncologists are not convinced that ip chemotherapy is of benefit to prevent recurrence of peritoneal surface disease. Data from prospective trials and from clinical observations suggest that ip chemotherapy can reduce or eliminate the recurrence of peritoneal carcinomatosis after surgery to remove large-volume disease. Appendiceal mucinous neoplasms present the paradigm for successful management of peritoneal dissemination. Less cancer invasion, minimal (2%) incidence of lymph nodal or liver metastases, and minimal or absent disease on small bowel surfaces work together to allow successful management. In a recent systematic review by Yan and colleagues, approximately 65% of patients were documented to be disease-free at 5 years. (12) In patients with colon cancer carcinomatosis Verwaal and colleagues performed a single institution 122
5 Sugarbaker, Cancerología 3 (2008): randomized trial of cytoreduction plus HIPEC versus standard of care with systemic chemotherapy. (13) In the group given combined treatment the median survival was 43 months vs. 23 months in the control group. Glehen and colleagues performed a retrospective study of 523 patients with colon cancer carcinomatosis treated by cytoreductive surgery plus HIPEC, EPIC or both HIPEC and EPIC. (14) The median survival was 32 months in patients who had a complete cytoreduction. These results were greatly improved when compared to the 6-12 month median survival in carcinomatosis patients treated by systemic chemotherapy. Several prospective randomized studies in peritoneal carcinomatosis from gastric cancer have been reported. The meta-analysis of eight trials was reported by Yan and coworkers. (15) There was an improved survival in all seven trials using perioperative ip chemotherapy. Indications for the combined use of surgery to remove all visible abdominal or pelvic cancer and perioperative intraperitoneal chemotherapy to eradicate microscopic disease remains controversial. In experienced centers the application of this new and more comprehensive cancer management strategy remains broad. The conditions that benefit are listed in Table 2. The continued expansion of the use of HIPEC and EPIC to improve the results of treatment of abdominal and pelvic cancer remains a work in progress. References 1. Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker PH. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Belg Chir 1994; 94: Sugarbaker PH, Graves T, DeBruijn EA, et al. Rationale for early perioperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 1990; 50: Sugarbaker PH, Cunliffe W, Israel M, Sweatman TW. Early perioperative intraperitoneal adriamycin: pharmacologic studies and a preliminary clinical report. Reg Cancer Treat 1991; 4: Markman M. Intraperitoneal taxol. (In) Sugarbaker PH (ed). Peritoneal Carcinomatosis: Drugs and Diseases. Kluwer: Boston, Pestieau SR, Stuart OA, Chang D et al. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 1998; 84: Sugarbaker PH. Cytoreductive Surgery and Intraperitoneal Chemotherapy: A Manual for Physicians and Nurses. Ludann: Grand Rapids, Jacquet P, Jelinek JS, Chang D, et al. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery.[erratum appears in J Am Coll Surg 1996 Jan;182(1):80]. Journal of the American College of Surgeons 1995; 181: Steller EPH. Comparison of four scoring models for an intraperitoneal immunotherapy model. In: Enhancement and Abrogation: Modifications of Host Immune Status Influence IL-2 and LAK Cell Immunotherapy. Erasmus Universitait: Rotterdam, 1998, pp Table 2 Current indications for combined treatment using cytoreductive surgery and perioperative ip chemotherapy. Symptomatic malignant ascites Pseudomyxoma peritonei after complete cytoreduction Peritoneal mesothelioma after complete cytoreduction Primary colon or rectal cancer Small volume and limited distribution peritoneal seeding Perforated colon cancer Colon cancer with adjacent organ involvement Colon cancer with spread to the ovaries Colon cancer with positive ip cytology Tumor spill with resection of primary colon or rectal cancer Recurrent colon or rectal cancer with carcinomatosis Small volume and limited-distribution of peritoneal seeding Colon cancer causing Krukenberg ovarian tumor Tumor spill with resection of recurrent cancer Complete cytoreduction of recurrent disease at more than a single site Recurrent ovarian cancer with spread limited to peritoneal surfaces Limited or absent iv chemotherapy options Long free interval between initial treatment and recurrence Primary gastric cancer after complete resection with limited peritoneal seeding Primary of recurrent abdominopelvic sarcoma Sarcomatosis following complete cytoreduction Primary abdominopelvic sarcoma with equivocal margins of resection Primary abdominopelvic sarcoma with tumor spill during resection 123
6 Overview of Peritoneal Carcinomatosis 9. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999; 23: Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. European Journal of Cancer 1999; 35: Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnoses and staging of patients with recurrent abdominopelvic sarcoma for treatment. (In) Sugarbaker PH (ed). Peritoneal Carcinomatosis: Principles of Management. Kluwer: Boston, 1996, Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007; 14: Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multiinstitutional study. J Clin Oncol 2004; 22: Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for advanced gastric cancer. Ann Surg Oncol 2007; 14:
Peritoneal Surface Malignancies. Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA
Peritoneal Surface Malignancies Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA Cancer dissemination routes Hematogenous metastases Lymphatic metastases Implants on peritoneal surfaces Surgically
More informationCytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future Mazin Al-kasspooles, MD Associate Professor of Surgery Division of Surgical Oncology Director, Regional Therapy
More informationLuis D. Carcorze Soto, MD PGY-3
Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:
More informationChirurgia Avanzata Del Carcinoma Ovarico Nuove Strategie A Confronto Ovarian Cancer Advanced Surgery New Strategies in Comparison
Peritoneal dissection and intraperitoneal chemotherapy under hyperthermic conditions. If you select the right patients long-term survival can be achieved. Chirurgia Avanzata Del Carcinoma Ovarico Nuove
More informationCytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma
Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma
More informationCytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface
J. Exp. Clin. Cancer Res., 22, 4, 2003 - Supplement Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface Malignancy Yan T.D., Esquivel J., Carmignani
More informationIntraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD KCHC 8/29/13 52 y.o. F presented with severe pain in the right back and right flank, sharp, 8 out of 10, for 7 days.
More informationComments: Policy Accepted during 2013 Annual Review with no changes.
Health Plan Coverage Policy ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 09/18/2013 Title: Cytoreduction Surgery with Hyperthermic Intraperitoneal Chemotherapy Comments: Policy
More informationINTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS
INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS Description of Treatment A major difficulty in treating
More informationPopulation Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure
Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure Eddy Cotte, Brigitte Tranchand, Annie-Claude Beaujard, François-Noël
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2016 3/2017
More informationRachel E. Kirby, Jing Zhao, Terence Chua, Winston Liauw and David L. Morris *
Send Orders for Reprints to reprints@benthamscience.net The Open Surgical Oncology Journal, 2014, 5, 1-5 1 Open Access Avoidance of Early Post-Operative Intraperitoneal Chemotherapy (EPIC) Following Peritonectomy
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
MEDICAL POLICY INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: CS141.A Effective Date: September 1, 2015 Table of Contents COVERAGE RATIONALE DEFINITIONS... APPLICABLE CODES..
More informationPeritoneal Carcinosis
Peritoneal Carcinosis What is it and how to cure it Peritoneum Peritoneum is a thin and transparent membrane that covers the internal part of the abdominal and pelvic cavity and all the viscera contained
More informationColumbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
More informationGastrointestinal Oncology Peritoneal Mesothelioma
Gastrointestinal Oncology Two Decades of Progress in the Management of a Rare Disease Paul H Sugarbaker, MD, FACS, FRCS Medical Director, Center for Gastrointestinal Malignancies, MedStar Washington Hospital
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationLaparoscopic Hyperthermic Intraperitoneal Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature
Ann Surg Oncol DOI 10.1245/s10434-012-2360-0 ORIGINAL ARTICLE REVIEW ARTICLE Laparoscopic Hyperthermic Intra Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature Enrico Facchiano,
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers NMP346 Effective Date*: June 2007 Updated: November 2014 This National Medical Policy
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationA succesfull case of HIPEC in a peritoneal mesothelioma patient
A succesfull case of HIPEC in a peritoneal mesothelioma patient Firmino, NLJ¹²; Miranda, E¹³; Oliveira, DA ²; Lima, MBA ¹²; Diniz, AF ¹²; Gomes, GES ¹²; Azevedo, LW ¹²; Soares,MC¹²; Gomes, ASA³. ¹Pernambuco
More informationHospital: IRB #: Principal Phone Fax Email Investigator: Dr. A. Co-investigators: Dr. C Dr. D Dr. E Dr. F
Title: Protocol for the Implementation of Treatment of Patients with Peritoneal Surface Malignancy with Hyperthermic Intraoperative Intraperitoneal Chemotherapy and Normothermic Early Postoperative Intraperitoneal
More informationPeritoneal Carcinomatosis: Pathophysiology, Prevention, and Treatment
Peritoneal Carcinomatosis: Pathophysiology, Prevention, and Treatment Wim Ceelen, MD, PhD, FACS GI Surgery, UZ Gent KAGB 27/4/2013 Overview What is peritoneal carcinomatosis? Rationale for IP drug delivery
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly
Huang et al. World Journal of Surgical Oncology (2015) 13:262 DOI 10.1186/s12957-015-0682-7 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Cytoreductive surgery and perioperative intraperitoneal chemotherapy
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationOncologist. The. Clinical Pharmacology. Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy
The Oncologist Clinical Pharmacology Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy PAUL H. SUGARBAKER, a JORGE TORRES MORA, b PABLO CARMIGNANI, a O. ANTHONY
More informationPost-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
More informationClinical Commissioning Policy: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma
Clinical Commissioning Policy: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Reference: NHS England B03/P/a 1 Information Reader Box (IRB) to be inserted
More informationClinical Commissioning Policy: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma
Clinical Commissioning Policy: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Reference: NHS England A08/P/c 2 NHS England INFORMATION READER BOX Directorate
More informationPRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology
PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationHow To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationClinical Policy Bulletin: Hyperthermia in Cancer Therapy
Hyperthermia in Cancer Therapy Page 1 of 28 Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Clinical Policy Bulletin: Hyperthermia in Cancer Therapy Number:
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationPrincipal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
More information4 th Edition Paul H. Sugarbaker, MD, FACS, FRCS
December 5, 2005 Technical Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynecologic Malignancy
More informationEvidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
More informationSurgical Staging of Endometrial Cancer
Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging
More information2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationColorectal Cancer Treatment
Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.
More informationMR Imaging of Peritoneal Malignancy Russell N. Low, MD
MR Imaging of Peritoneal Malignancy Russell N. Low, MD From: Sharp and Children's MRI Center and Sharp HealthCare, 7901 Frost Street, San Diego, California, 92123. Phone: (858) 939-3600. Email: rlow@ucsd.edu
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationSelection of patients and staging of peritoneal surface malignancies
Online Submissions: http://www.wjgnet.com/1948-5204office wjgo@wjgnet.com doi:10.4251/wjgo.v2.i1.31 World J Gastrointest Oncol 2010 January 15; 2(1): 31-35 ISSN 1948-5204 (online) 2010 Baishideng. All
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationPseudomyxoma Peritonei Where are we in 2014?
Pseudomyxoma Peritonei Where are we in 2014? Santiago González-Moreno, MD, PhD Head, Department of GI Surgical Oncology Peritoneal Surface Oncology Program Medical Director * * * * * * * * * * * * French
More informationA PATIENT S GUIDE TO ABLATION THERAPY
A PATIENT S GUIDE TO ABLATION THERAPY THE DIVISION OF VASCULAR/INTERVENTIONAL RADIOLOGY THE ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL Treatment options for patients with cancer continue to expand, providing
More informationMEDICAL POLICY SUBJECT: HYPERTHERMIA AS A CANCER TREATMENT. POLICY NUMBER: 2.01.25 CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: HYPERTHERMIA AS A CANCER PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationOsteosarcoma: treatment beyond surgery
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
More informationTreating Mesothelioma - A Quick Guide
Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information
More information1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet
More informationJ of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063
PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationRESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
More informationINTRODUCTION. Abstract Background. 3 Centre hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bé
Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey Pablo Ortega-Deballon 1 2 *, Olivier Glehen 3, Edward Levine 4, Pompiliu Piso, Paul H. Sugarbaker 6, Andrea
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationMesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology
MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image
More informationTreatment options for recurrent ovarian cancer
Treatment options for recurrent ovarian cancer There are a number of treatment options for women with recurrent ovarian cancer. Chemotherapy is the treatment most commonly offered and on occasion, surgery
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationOverview of Gynaecologic Cancer
Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms
More informationCarcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is
More informationCytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma
Original Article 291 Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma Grace HC Tan, 1 MBBS (London), MRCS (Edinburgh), Michelle Cheung, 1 MBBCh
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationHosts. New Methods for Treating Colorectal Cancer
Hosts Anees Chagpar MD Associate Professor of Surgical Oncology Francine MD Professor of Medical Oncology New Methods for Treating Colorectal Cancer Guest Expert: Scott, MD Associate Professor in the Department
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationYue Zhu, Nader Hanna, Cherif Boutros, H. Richard Alexander Jr. Background
Review Article Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases Yue
More informationEvidence-Based Medicine in the Treatment of Peritoneal Carcinomatosis: Past, Present, and Future
2009;100:335 344 Evidence-Based Medicine in the Treatment of Peritoneal Carcinomatosis: Past, Present, and Future AVIRAM NISSAN, MD, 1,2 * ALEXANDER STOJADINOVIC, MD, 3,4 ALFREDO GAROFALO, MD, 5{ JESUS
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationPeritoneal Mesothelioma: The Columbia Experience
48 Peritoneal Mesothelioma: The Columbia Experience Jennifer A. Wagmiller, Mary-Louise Keohan, John A. Chabot, Karen Fountain, Mary Hesdorffer, and Robert N. Taub Malignant peritoneal mesothelioma is a
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationESSO Course on Peritoneal Surface Malignancy
ESSO Course on Peritoneal Surface Malignancy In partnership with The Christie School of Oncology 08-09 October 2015 MANCHESTER (UK) ESSO Course on Peritoneal Surface Malignancy Chair: Sarah O Dwyer, The
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationYour bladder cancer diary. WA Cancer and Palliative Care Network
Your bladder cancer diary WA Cancer and Palliative Care Network Patient information and persons to contact Your Name Date of Birth URMN (Patient Hospital Unit Number) Address Phone Mobile GP Name Phone
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationPATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.
PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES. Radiation Oncology Sidney Kimmel Cancer Center at Johns Hopkins Last
More informationUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org
Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA
More informationContents. Updated July 2011
- Updated July 2011 Guideline Authors: Todd S. Crocenzi, M.D.; Mark Whiteford, M.D.; Matthew Solhjem, M.D.; Carlo Bifulco, M.D.; Melissa Li, M.D.; Christopher Cai, M.D.; and James Durham, M.D. Contents
More informationUnderstanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE
Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 8 References... 8 Effective
More informationCANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationIntraperitoneal chemotherapy
Critical Reviews in Oncology/Hematology 31 (1999) 239 246 Intraperitoneal chemotherapy Maurie Markman * Department of Hematology/Medical Oncology, The Cle eland Clinic Taussig Cancer Center, The Cle eland
More informationProtocol. Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies (20307) (Formerly Chemotherapy for the Treatment of Pseudomyxoma Peritonei, Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal
More informationLIVER CANCER AND TUMOURS
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
More informationLYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
More informationIntraperitoneal Chemotherapy
Intraperitoneal Chemotherapy What is Intraperitoneal (IP) Chemotherapy? Intraperitoneal (IP) chemotherapy is a way to put some of your chemotherapy into your abdomen (also called the peritoneal cavity)
More informationrestricted to certain centers and certain patients, preferably in some sort of experimental trial format.
Managing Pancreatic Cancer, Part 4: Pancreatic Cancer Surgery, Complications, & the Importance of Surgical Volume Dr. Matthew Katz, Surgeon, MD Anderson Cancer Center, Houston, TX I m going to talk a little
More informationO. Glehen 1,2, E. Cotte 1,2, J. C. Lifante 1,2, C. Arvieux 2,3, N. Moles 1, C. Brigand 2,4, A. C. Beaujard 1,2, Y. François 1,2, F. N.
Acta chir belg, 2006, 106, 285-290 Peritoneal Carcinomatosis in Digestive Cancers : Cytoreductive Surgery Combined with Intraperitoneal Chemohyperthermia. The Experience in Centre Hospitalier et Universitaire
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationJ Clin Oncol 27:6237-6242. 2009 by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 36 DECEMBER 20 2009 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma:
More informationEndometrial cancer-carcinoma of the lining of the uterus-is the most common gynecologic
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4th Edition 2001 Uterus: Endometrial Carcinoma Jeffrey L. Stern, MD Endometrial
More informationEffects of sex hormones on survival of peritoneal mesothelioma
Huang et al. World Journal of Surgical Oncology (2015) 13:210 DOI 10.1186/s12957-015-0624-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Effects of sex hormones on survival of peritoneal mesothelioma
More information